Addressing DDRi Toxicity: Dosing Schedules, Combination Studies & Biomarkers

Time: 10:00 am
day: Day Two


  • Weighing up the costs and benefits of alternative dosing schedules and tailoring them to specific patients
  • Refining specificity: targeting tumors using the different screening platform
  • Evaluating common biomarker approaches to patient selection: BRCA screening, HHR gene panel tests and HRD genomic instability assays